Company Overview of AmVac AG
AmVac AG develops vaccines for the treatment and prevention of widespread infections and urogenital conditions. The company offers Gynevac, a platform for the treatment of urogenital conditions; MALP platform that enables the generation of a new class of vaccine adjuvants, which are mixed with vaccines to increase their efficacy; and Sendai, a virus vector platform that enables the generation of a new class of ‘semi-live’ vaccines for the prevention of respiratory syncytial virus infections. It also offers vaccines for the prevention of seasonal and pandemic influenza, chronic prostatitis, and benign prostate hyperplasia; and acute, subacute, and chronic gynecological inflammations. AmVac AG...
Founded in 2005
Key Executives for AmVac AG
Founder, Chief Executive Officer and Member of the Supervisory Board
Chairman of The Supervisory Board, Chief Legal Officer and Head of Operations
Head of Research & Development
Chief Information Officer
Compensation as of Fiscal Year 2014.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries